• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从受体结合动力学到信号转导;预测体内药物作用的缺失环节。

From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.

机构信息

Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands.

Fraunhofer IME Screening Port, Schnackenburgallee 114, D-22525, Hamburg, Germany.

出版信息

Sci Rep. 2017 Oct 26;7(1):14169. doi: 10.1038/s41598-017-14257-4.

DOI:10.1038/s41598-017-14257-4
PMID:29075004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5658448/
Abstract

An important question in drug discovery is how to overcome the significant challenge of high drug attrition rates due to lack of efficacy and safety. A missing link in the understanding of determinants for drug efficacy is the relation between drug-target binding kinetics and signal transduction, particularly in the physiological context of (multiple) endogenous ligands. We hypothesized that the kinetic binding parameters of both drug and endogenous ligand play a crucial role in determining cellular responses, using the NK1 receptor as a model system. We demonstrated that the binding kinetics of both antagonists (DFA and aprepitant) and endogenous agonists (NKA and SP) have significantly different effects on signal transduction profiles, i.e. potency values, in vitro efficacy values and onset rate of signal transduction. The antagonistic effects were most efficacious with slowly dissociating aprepitant and slowly associating NKA while the combination of rapidly dissociating DFA and rapidly associating SP had less significant effects on the signal transduction profiles. These results were consistent throughout different kinetic assays and cellular backgrounds. We conclude that knowledge of the relationship between in vitro drug-target binding kinetics and cellular responses is important to ultimately improve the understanding of drug efficacy in vivo.

摘要

药物发现中的一个重要问题是如何克服由于疗效和安全性不足而导致的高药物淘汰率这一重大挑战。在理解药物疗效决定因素方面的一个缺失环节是药物-靶标结合动力学与信号转导之间的关系,特别是在(多种)内源性配体的生理背景下。我们假设,药物和内源性配体的动力学结合参数在确定细胞反应方面起着关键作用,以 NK1 受体作为模型系统。我们证明,两种拮抗剂(DFA 和阿瑞匹坦)和内源性激动剂(NKA 和 SP)的结合动力学对信号转导谱(即效力值、体外疗效值和信号转导起始速率)具有显著不同的影响。缓慢解离的阿瑞匹坦和缓慢结合的 NKA 具有最有效的拮抗作用,而快速解离的 DFA 和快速结合的 SP 的组合对信号转导谱的影响则不那么显著。这些结果在不同的动力学测定和细胞背景下都是一致的。我们得出结论,了解体外药物-靶标结合动力学与细胞反应之间的关系对于最终提高对体内药物疗效的理解是很重要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/6ae3c98acfe2/41598_2017_14257_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/297dc781ef59/41598_2017_14257_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/f3a0ea218dec/41598_2017_14257_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/048898a9020b/41598_2017_14257_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/fbc567c21802/41598_2017_14257_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/6ae3c98acfe2/41598_2017_14257_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/297dc781ef59/41598_2017_14257_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/f3a0ea218dec/41598_2017_14257_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/048898a9020b/41598_2017_14257_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/fbc567c21802/41598_2017_14257_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be2f/5658448/6ae3c98acfe2/41598_2017_14257_Fig5_HTML.jpg

相似文献

1
From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.从受体结合动力学到信号转导;预测体内药物作用的缺失环节。
Sci Rep. 2017 Oct 26;7(1):14169. doi: 10.1038/s41598-017-14257-4.
2
Kinetic binding and activation profiles of endogenous tachykinins targeting the NK1 receptor.内源性速激肽作用于NK1受体的动力学结合和激活曲线
Biochem Pharmacol. 2016 Oct 15;118:88-95. doi: 10.1016/j.bcp.2016.08.004. Epub 2016 Aug 5.
3
Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.肝癌细胞表达截断的神经激肽-1 受体,阿瑞匹坦可在体外和体内抑制其生长。
J Hepatol. 2014 May;60(5):985-94. doi: 10.1016/j.jhep.2013.12.024. Epub 2014 Jan 8.
4
Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.靶向 SP/NK1R 系统治疗宫颈癌的体外潜在疗效。
Mol Biol Rep. 2022 Feb;49(2):1067-1076. doi: 10.1007/s11033-021-06928-3. Epub 2021 Nov 12.
5
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.非肽类神经激肽-1 受体拮抗剂的再利用作为抗肿瘤药物:阿瑞匹坦面临的紧迫挑战。
Int J Mol Sci. 2023 Nov 3;24(21):15936. doi: 10.3390/ijms242115936.
6
Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon.豚鼠回肠和近端结肠环形肌中速激肽NK1和NK2受体的比较。
Br J Pharmacol. 1994 May;112(1):150-60. doi: 10.1111/j.1476-5381.1994.tb13045.x.
7
The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.SP/NK1R 对前列腺癌细胞谷胱甘肽还原酶和硫氧还蛋白蛋白表达和活性的影响。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):5875-5882. doi: 10.1007/s00210-024-02996-x. Epub 2024 Feb 9.
8
Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.点突变增加了一种对神经激肽A、B和七肽具有高亲和力的NK1受体形式。
Br J Pharmacol. 1998 Sep;125(2):393-401. doi: 10.1038/sj.bjp.0702070.
9
The neuropeptide substance P regulates aldosterone secretion in human adrenals.神经肽 P 调节人肾上腺中的醛固酮分泌。
Nat Commun. 2020 May 29;11(1):2673. doi: 10.1038/s41467-020-16470-8.
10
Gastric chief cells possess NK1 receptors which mediate pepsinogen secretion and are regulated by agents that increase cAMP and phospholipase C.胃主细胞拥有NK1受体,该受体介导胃蛋白酶原的分泌,并受增加环磷酸腺苷(cAMP)和磷脂酶C的药物调节。
Biochim Biophys Acta. 1996 Jun 13;1312(2):105-16. doi: 10.1016/0167-4889(96)00026-2.

引用本文的文献

1
Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.观点:配体-受体结合动力学对G蛋白偶联受体治疗靶点的影响
ACS Pharmacol Transl Sci. 2020 Mar 18;3(2):179-189. doi: 10.1021/acsptsci.0c00012. eCollection 2020 Apr 10.
2
Bioluminescence Resonance Energy Transfer Based G Protein-Activation Assay to Probe Duration of Antagonism at the Histamine H Receptor.基于生物发光共振能量转移的 G 蛋白激活测定法探究组胺 H 受体拮抗剂的作用持续时间。
Int J Mol Sci. 2019 Jul 30;20(15):3724. doi: 10.3390/ijms20153724.

本文引用的文献

1
A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.一种适用于9种药物的通用多房室中枢神经系统分布模型结构可预测人脑靶部位浓度。
Pharm Res. 2017 Feb;34(2):333-351. doi: 10.1007/s11095-016-2065-3. Epub 2016 Nov 18.
2
Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.由缓慢解离动力学驱动的腺苷A2A受体激动剂持续效应的构效关系
Mol Pharmacol. 2017 Jan;91(1):25-38. doi: 10.1124/mol.116.105551. Epub 2016 Nov 1.
3
Kinetic Profile of Neuropeptide-Receptor Interactions.
神经肽-受体相互作用的动力学特征。
Trends Neurosci. 2016 Dec;39(12):830-839. doi: 10.1016/j.tins.2016.09.008. Epub 2016 Oct 25.
4
Kinetic binding and activation profiles of endogenous tachykinins targeting the NK1 receptor.内源性速激肽作用于NK1受体的动力学结合和激活曲线
Biochem Pharmacol. 2016 Oct 15;118:88-95. doi: 10.1016/j.bcp.2016.08.004. Epub 2016 Aug 5.
5
BRET-based β-arrestin2 recruitment to the histamine H1 receptor for investigating antihistamine binding kinetics.基于生物发光共振能量转移的β-抑制蛋白2募集至组胺H1受体以研究抗组胺药结合动力学
Pharmacol Res. 2016 Sep;111:679-687. doi: 10.1016/j.phrs.2016.07.034. Epub 2016 Jul 26.
6
In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant.体内靶标停留时间和动力学选择性:结合速率常数作为决定因素。
Trends Pharmacol Sci. 2016 Oct;37(10):831-842. doi: 10.1016/j.tips.2016.06.008. Epub 2016 Jul 6.
7
Equilibrium and kinetic selectivity profiling on the human adenosine receptors.人腺苷受体的平衡和动力学选择性分析
Biochem Pharmacol. 2016 Apr 1;105:34-41. doi: 10.1016/j.bcp.2016.02.018. Epub 2016 Feb 27.
8
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.GPCR变构调节剂发现中的实用策略与概念:代谢型谷氨酸受体的最新进展
Chem Rev. 2016 Jun 8;116(11):6707-41. doi: 10.1021/acs.chemrev.5b00656. Epub 2016 Feb 16.
9
Persistent GnRH receptor activation in pituitary αT3-1 cells analyzed with a label-free technology.利用无标记技术分析垂体 αT3-1 细胞中 GnRH 受体的持续激活。
Biosens Bioelectron. 2016 May 15;79:721-7. doi: 10.1016/j.bios.2015.12.066. Epub 2015 Dec 21.
10
The drug-target residence time model: a 10-year retrospective.药物-靶点停留时间模型:十年回顾。
Nat Rev Drug Discov. 2016 Feb;15(2):87-95. doi: 10.1038/nrd.2015.18. Epub 2015 Dec 18.